期刊文献+

双膦酸盐相关非典型股骨骨折的手术治疗 被引量:4

Surgical treatment for bisphosphonate-related atypical femoral fractures
下载PDF
导出
摘要 目的探讨手术治疗双膦酸盐相关非典型股骨骨折的疗效。方法回顾性分析2011年1月至2012年12月手术治疗的15例(15侧骨折)双膦酸盐相关非典型股骨骨折患者资料,平均年龄76.0±6.4岁(65~88岁)。所有病例骨折时髋部骨密度T值平均为-3.1±0.7(-1.8^-4.5)。9病例骨折部位位于转子下,6例位于股骨干。12例采用髓内针固定。3例采用钢板螺钉固定。术后观察患者的骨折愈合情况。结果所有患者术后均获骨性愈合,平均愈合时间为5.9±1.4个月(4~8个月)。无感染、骨折不愈合,内固定物松动或断裂,下肢深静脉血栓等并发症发生。不同固定方式骨折愈合时间无差异(t=1.56,P=0.14)。服药时间与骨折愈合时间无相关性(r=0.034,P=0.904)。结论手术治疗是双膦酸盐相关非典型股骨骨折的有效方法。 Objective To investigate the effect of surgical treatment for bisphosphonate-related atypical femoral fractures. Methods The clinical data of 15 patients with bisphosphonate-related atypical femoral fractures ( 15 sides), who received operations from January 2011 to December 2012, aging from 65 to 88 years old, with an average age of 76. 0 - 6.4 years old, were retrospectively analyzed. The average T-score of the hip BMD in all the cases was - 3.1 + 0. 7 ( 1.8 - - 4. 5). Nine cases were subtroehanteric fractures, and 6 cases were femoral shaft fractures. Twelve cases were operated using intramedullary nail fixation. Three cases were operated using steel screws. The healing of the fractures in all patients was observed. Results All fractures after the operations had healed, with an average healing duration of 5.9 ± 1.4 months, ranging from 4 to 8 months. No infection, nonunion, fixation loosening or rupture, deep vein thrombosis, and other complications occurred. No difference of healing duration in different fixation methods was observed (t = 1.56, P = 0. 14). No correlation between the duration of fracture healing and the period of medication was observed ( r = 0. 034, P = 0. 904). Conclusion Surgical treatment is an effective treatment for bisphosphonate-related atypical femoral fractures.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第11期1165-1169,共5页 Chinese Journal of Osteoporosis
关键词 股骨骨折 双膦酸盐类 非典型骨折 Femoral fractures Bisphosphonates Atypical fractures
  • 相关文献

参考文献26

  • 1Favus MJ. Bisphosphonates for osteoporosis[ J]. N Engl J Med, 2010,363:2027-2035.
  • 2Giusti A, Hamdy NA, Dekkers OM,et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features [ J ]. Bone, 2011,48:966-971.
  • 3Vigorita V J, Silver JS, Eisemon EO. Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report[ J]. Skeletal Radiol, 2012,41:861-865.
  • 4Haschka J, Kuhne F, Muschitz C,et al. The 5-year follow-up of a cortical stress fracture resulting in a spontaneous atypical subtrochanteric femoral fracture in a female patient with severe osteoporosis and bisphosphonate therapy over 15 years[ J]. Wien Klin Wochenschr, 2011, 123:684-687.
  • 5Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy[ J]. JAMA, 2010, 304 : 1480- 1484.
  • 6Wang Z, Bhattacharyya T. Trends in incidence of subtroehanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007 [ J]. J Bone Miner Res, 2011, 26:553-560.
  • 7Cermak K, Shumelinsky F, Alexiou J, et al. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy [ J ]. Clin Orthop Relat Res, 2010, 468: 1991-1996.
  • 8Alfahad A,Thet EM, Radwan F, et al. Spontaneous Incomplete transverse subtroehanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report [J]. J Med Case Rep, 2012,6:272.
  • 9Rachkidi R, Sari-Leret ML, Wolff S. Atypical bilateral pedicle fracture in long-term bisphosphonate therapy [ J ]. Spine, 2011, 36 : E1769-73.
  • 10Breglia MD, Carter JD. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy [ J ]. J Clin Rheumatol, 2010,16 : 76-78.

同被引文献60

  • 1姜洪池,孙备,王刚.快速康复外科的新理念值得重视[J].中华外科杂志,2007,45(9):577-579. 被引量:127
  • 2Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy [ J]. J Clin Endoerinol Metab,2005,90(3) : 1294-1301.
  • 3Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features [J]. Bone, 2011,48 (5) :966-971. DOI: 10. 1016/j. bone. 2010. 12. 033.
  • 4Gunawardena I, Baxter M, Rasekh Y. Bisphosphonate-related subtrochanteric femoral fractures [ J ]. Am J Geriatr Pharmacother, 2011,9(3) :194-198. DOI: 10. 1016/j. amjopharm. 2011. 02. 009.
  • 5Vigorita VJ, Silver JS, Eisemon EO. Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report [ J ]. Skeletal Radiol, 2012,41 ( 7 ) : 861-865. DOI : 10. 1007/s00256-012-1407-4.
  • 6Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research [ J ]. J Bone.Miner Res, 2010,25 ( 11 ) :2267-2294. DOI: 10. 1002/jbmr. 253.
  • 7Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research [ J 1. J Bone Miner Res, 2014,29(1):1-23. DOI: 10. 1002/jbmr. 1998.
  • 8Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy I J 1. JAMA, 2010,304 ( 13 ) : 1480-1484. DOI: 10. 1001/jama. 2010. 1360.
  • 9Thoresen BO, Alho A, Ekeland A, et al. Interlocking intramedullary nailing in femoral shaft fractures. A report of forty- eight eases~J~. J Bone Joint Surg Am,1985,67(9) :1313-1320.
  • 10Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fraeture intervention trial research group [ J 1. Lancet, 1996,348 ( 9041 ) : 1535-1541.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部